
Equilibrium THERAPEUTICS

iit STARTUPS

Durable β-cell Replacement Therapy for Functional Cure of T1 Diabetes

Bhushan N. Kharbikar, PhD

Co-founder, CEO



Proprietary and Confidential - Do Not Distribute

Company: Equilibrium Therapeutics (EQTX)

Equilibrium THERAPEUTICS

A full-stack β-cell replacement therapy for a durable, controllable functional cure for T1 diabetes.

$1.4M non-dilutive
(Breakthrough T1D with Brown University)


US patent filed
(Design, manufacturing and tx use covered in IP)

Proven in animals
(first-in-class strong preclinical evidences)

CDMO MOU in US
(Contract manufacturing partner for cells)

Nature portfolio
(research publication is in revision)


Problem: T1 Diabetes has **no cure**



~9.2M	#1	~174K	~$813B
Patients globally	Organ failure	Premature deaths/y	US economic burden

Adapted from - Aydin S et al.,. Adv Exp Med Biol, 1247. *T1D (UK, NHS data), IDF Atlas 11th Ed. 2025 · Lancet DE 2022 · ISPOR 2025*

Gap: β cells replacement faces three major hurdles




Insulin independence post-transplantation is never reached or is not durable

Proprietary and Confidential - Do Not Distribute

Adapted from - Desai T.A., Tang Q. (2018). Islet encapsulation therapy: racing towards the finish line? Nat Rev Endocrinol, 14, 630–632.

Solution → **product**: Our full stack therapeutic platform



Our technology integrates function, durability, and clinical control

Proprietary and Confidential - Do Not Distribute

Results: First-in-class, 1-year of preclinical evidence


Control

Transplant under the skin




Subcutaneous transplant

Durability



Long-term graft survival


Function



Strong insulin response

Proprietary and Confidential - Do Not Distribute


Landscape: Competitors solve pieces, we integrate systems



The moat is a systems integration advantage.

Proprietary and Confidential - Do Not Distribute

Market & Business model: ~$3B beachhead, unstable T1D patients



A staged market ladder connects patients, endpoints and value

Proprietary and Confidential - Do Not Distribute

*unit price matched conservatively with current trend & Lantidra (Human islet tx)

Founding team: Deep scientific and executive leadership




Bhushan N. Kharbikar, PhD

Co-founder & CEO

- *Senior Scientist, Brown University*
- *Ex Asst. Professional Researcher, UCSF*

- Leader in bioengineering, micro/nanofabrication, and biomaterials for cell therapies and transplants
- Decorated innovator (Breakthrough T1D, Lockheed Martin, Stanford Med, DBT India, Samsung)



Prof. Tejal A. Desai, PhD


Co-founder

- *Dean of Engineering, Brown University*
- *Prof. and Ex Chair of Bioengineering, UCSF*

- Pioneer in bioengineering, biomaterials and micro/nanotechnology for cell and drug delivery
- Decorated innovator and Strategic scientific leadership (Brown, UC Berkeley, UCSF)
- Serial entrepreneur (Oculinea, Encellin)

Funding ask: Capitalization & clinical inflection

Deploying **$30M (Seed+)** to reach clinical-grade **manufacturing** & **IND clearance with US FDA**



CMC – Chemistry, Manufacturing, and Controls
cGMP – Current Good Manufacturing Practices
IND – Investigational New Drug
GLP – Good Laboratory Practice
IP – Intellectual Property
US FDA – United States Food and Drug Administration

Proprietary and Confidential - Do Not Distribute

Equilibrium THERAPEUTICS

From lifelong T1 diabetes management to functional cure

$1.4M non-dilutive
(Breakthrough T1D with Brown University)

Deploying **$30M (Seed+)** to reach clinical-grade **manufacturing** & **IND clearance with US FDA**

bhushannk.iitb@gmail.com

https://www.linkedin.com/in/dr-bhushan-kharbikar/

Startup: Equilibrium Therapeutics

https://iitstartups.org/us-demoday-cohort-15/

SCAN

https://zfrmz.com/p19jyuetieRIM6wRPsfF

Equilibrium Therapeutics is building a full-stack β-cell replacement therapy toward a durable, controllable functional cure for T1 diabetes.



Bhushan N. Kharbikar

Founder & CEO

bhushannk.iitb@gmail.com

+1 628 999 1004

https://www.linkedin.com/in/dr-bhushan-kharbikar/

https://calendly.com/eqtx/30min